Antifungal Potential of Synthetic Peptides against Cryptococcus neoformans: Mechanism of Action Studies Reveal Synthetic Peptides Induce Membrane–Pore Formation, DNA Degradation, and Apoptosis

Cryptococcus neoformans is a human-pathogenic yeast responsible for pneumonia and meningitis, mainly in patients immunocompromised. Infections caused by C. neoformans are a global health concern. Synthetic antimicrobial peptides (SAMPs) have emerged as alternative molecules to cope with fungal infections, including C. neoformans. Here, eight SAMPs were tested regarding their antifungal potential against C. neoformans and had their mechanisms of action elucidated by fluorescence and scanning electron microscopies. Five SAMPs showed an inhibitory effect (MIC50) on C. neoformans growth at low concentrations. Fluorescence microscope (FM) revealed that SAMPs induced 6-kDa pores in the C. neoformans membrane. Inhibitory assays in the presence of ergosterol revealed that some peptides lost their activity, suggesting interaction with it. Furthermore, FM analysis revealed that SAMPs induced caspase 3/7-mediated apoptosis and DNA degradation in C. neoformans cells. Scanning Electron Microscopy (SEM) analysis revealed that peptides induced many morphological alterations such as cell membrane, wall damage, and loss of internal content on C. neoformans cells. Our results strongly suggest synthetic peptides are potential alternative molecules to control C. neoformans growth and treat the cryptococcal infection.

[1]  J. Oliveira,et al.  Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2 , 2022, ACS omega.

[2]  Gregory R. Wiedman,et al.  Development of Antifungal Peptides against Cryptococcus neoformans; Leveraging Knowledge about the cdc50Δ Mutant Susceptibility for Lead Compound Development , 2022, Microbiology spectrum.

[3]  F. Azam,et al.  In silico and in vitro studies on the inhibition of laccase activity by Ellagic acid: Implications in drug designing for the treatment of Cryptococcal infections. , 2022, International journal of biological macromolecules.

[4]  B. Zwaan,et al.  Tackling the emerging threat of antifungal resistance to human health , 2022, Nature reviews. Microbiology.

[5]  J. Geddes-McAlister,et al.  Peptidases: promising antifungal targets of the human fungal pathogen, Cryptococcus neoformans , 2022, FACETS.

[6]  D. A. Santos,et al.  Fungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond , 2021, PLoS pathogens.

[7]  Khaled S. Allemailem,et al.  Liposomal Ellagic Acid Alleviates Cyclophosphamide-Induced Toxicity and Eliminates the Systemic Cryptococcus neoformans Infection in Leukopenic Mice , 2021, Pharmaceutics.

[8]  Bessi Qorri,et al.  Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells , 2020, Drug design, development and therapy.

[9]  J. Oliveira,et al.  Synthetic antimicrobial peptides: From choice of the best sequences to action mechanisms. , 2020, Biochimie.

[10]  Changlin Zhou,et al.  Antifungal activity of peptide MSI-1 against Cryptococcus neoformans infection in vitro and in murine cryptococcal meningoencephalitis , 2020, Peptides.

[11]  I. M. Vasconcelos,et al.  RcAlb-PepII, a synthetic small peptide bioinspired in the 2S albumin from the seed cake of Ricinus communis, is a potent antimicrobial agent against Klebsiella pneumoniae and Candida parapsilosis. , 2020, Biochimica et biophysica acta. Biomembranes.

[12]  Elizabeth R. Ballou,et al.  A titanic drug resistance threat in Cryptococcus neoformans. , 2019, Current opinion in microbiology.

[13]  Maria Izabel Florindo Guedes,et al.  Role of membrane sterol and redox system in the anti-candida activity reported for Mo-CBP2, a protein from Moringa oleifera seeds. , 2019, International journal of biological macromolecules.

[14]  Hsin-Yun Sun,et al.  Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. , 2019, AIDS (London).

[15]  I. Spriet,et al.  Antifungal drugs: What brings the future? , 2019, Medical mycology.

[16]  T. F. Martins,et al.  Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII are synthetic antimicrobial peptides active against human pathogens by stimulating ROS generation and increasing plasma membrane permeability. , 2019, Biochimie.

[17]  E. Ermakova,et al.  Effect of ergosterol on the fungal membrane properties. All-atom and coarse-grained molecular dynamics study. , 2017, Chemistry and physics of lipids.

[18]  L. Cowen,et al.  Molecular Evolution of Antifungal Drug Resistance. , 2017, Annual review of microbiology.

[19]  D. Boulware,et al.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. , 2017, The Lancet. Infectious diseases.

[20]  Teng Zhang,et al.  Kilogram-Scale Synthesis of Osteogenic Growth Peptide (10–14) Using a Fragment Coupling Approach , 2015 .

[21]  Shabana I. Khan,et al.  Discovery of Short Peptides Exhibiting High Potency against Cryptococcus neoformans. , 2014, ACS medicinal chemistry letters.

[22]  E. Swoboda-Kopeć,et al.  Candida albicans morphologies revealed by scanning electron microscopy analysis , 2013, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[23]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[24]  S. Janssens,et al.  The PIDDosome, DNA-damage-induced apoptosis and beyond , 2011, Cell Death and Differentiation.

[25]  R. Prasad,et al.  Antifungal activity of novel synthetic peptides by accumulation of reactive oxygen species (ROS) and disruption of cell wall against Candida albicans , 2011, Peptides.

[26]  Yibing Huang,et al.  Alpha-helical cationic antimicrobial peptides: relationships of structure and function , 2010, Protein & Cell.

[27]  Xiaorong Lin.  Cryptococcus neoformans: morphogenesis, infection, and evolution. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[28]  E. Mylonakis,et al.  Antifungal use in HIV infection , 2002, Expert opinion on pharmacotherapy.